Core Viewpoint - Health 160, a Chinese pharmaceutical and health product wholesaler, has successfully completed its IPO subscription with a significant oversubscription rate of 503.8 times, indicating strong market interest [1][2]. Group 1: IPO Details - Health 160's IPO subscription period was from September 9 to September 12, with a total subscription amount of at least HKD 252.4 billion as of September 12 [1]. - The company plans to issue 33.6455 million shares at a price of HKD 14.86 per share, aiming to raise approximately HKD 500 million [1]. - The public offering accounts for about 10% of the total shares, while international offerings make up approximately 90%, with an additional 15% over-allotment option [1]. Group 2: Use of Proceeds - The net proceeds from the IPO will be allocated as follows: 40% for expanding medical resource coverage and increasing platform traffic, 30% for enhancing R&D capabilities, 10% for diversifying products and services, 10% for strategic partnerships and acquisitions, and 10% for working capital and general corporate purposes [1]. Group 3: Company Overview - Health 160 is described as an experienced wholesaler of pharmaceutical and health products, as well as a leading provider of digital healthcare solutions [2]. - The company has connected over 44,600 healthcare institutions through its online platform, including more than 14,400 hospitals and over 30,200 grassroots healthcare institutions [2]. - Financially, the company reported revenues of approximately RMB 526 million, RMB 629 million, RMB 621 million, and RMB 100 million for the fiscal years ending March 31 for 2022, 2023, 2024, and 2025, respectively, with corresponding losses of RMB 120 million, RMB 106 million, RMB 108 million, and RMB 17.128 million [2].
健康160招股结束 孖展逾252亿港元超购504倍